HK1040184A1 - 治療青光眼之組合療法 - Google Patents

治療青光眼之組合療法

Info

Publication number
HK1040184A1
HK1040184A1 HK02101195.9A HK02101195A HK1040184A1 HK 1040184 A1 HK1040184 A1 HK 1040184A1 HK 02101195 A HK02101195 A HK 02101195A HK 1040184 A1 HK1040184 A1 HK 1040184A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
treating glaucoma
glaucoma
treating
therapy
Prior art date
Application number
HK02101195.9A
Other languages
English (en)
Inventor
Desantis Louis Jr
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of HK1040184A1 publication Critical patent/HK1040184A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02101195.9A 1999-03-12 2002-02-19 治療青光眼之組合療法 HK1040184A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/005423 WO2000054810A1 (en) 1999-03-12 1999-03-12 Combination therapy for treating glaucoma

Publications (1)

Publication Number Publication Date
HK1040184A1 true HK1040184A1 (zh) 2002-05-31

Family

ID=22272341

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101195.9A HK1040184A1 (zh) 1999-03-12 2002-02-19 治療青光眼之組合療法

Country Status (5)

Country Link
EP (1) EP1169061A1 (zh)
AU (1) AU3082999A (zh)
CA (1) CA2368242A1 (zh)
HK (1) HK1040184A1 (zh)
WO (1) WO2000054810A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
EP1768656A4 (en) * 2004-07-22 2008-01-23 Vanda Pharmaceuticals Inc TREATMENT OF OCULAR DISEASES
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
EP3421030A1 (en) 2009-11-09 2019-01-02 Allergan, Inc. Compositions and methods for stimulating hair growth
CA2807081C (en) 2010-07-29 2018-09-18 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861079A1 (en) * 1995-11-17 1998-09-02 Alcon Laboratories, Inc. Combination therapy for treating glaucoma

Also Published As

Publication number Publication date
WO2000054810A1 (en) 2000-09-21
CA2368242A1 (en) 2000-09-21
EP1169061A1 (en) 2002-01-09
AU3082999A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
GB9911863D0 (en) Therapeutic agents
GB9905010D0 (en) Therapeutic agents
HK1040184A1 (zh) 治療青光眼之組合療法
GB9904786D0 (en) Therapeutic agents
EP1007028A4 (en) TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
AU2042301A (en) 1-aminoalkyl-1H-indoles for treating glaucoma
GB9930570D0 (en) Therapy
IL136960A0 (en) Combination therapy for the treatment of migraine
GB9911881D0 (en) Therapeutic agents
GB9907243D0 (en) Therapy
AU2266801A (en) Combination therapy for treating neurodegenerative disease
GB9903476D0 (en) Therapeutic agents
HK1050897A1 (en) Pyranoindoles for treating glaucoma
GB9914744D0 (en) Therapeutic agents
GB9903119D0 (en) Therapeutic agents
IL136962A0 (en) Combination therapy for the treatment of migraine
IL136025A0 (en) Combination therapy for the treatment of migraine
GB9914745D0 (en) Therapeutic agents
GB9914742D0 (en) Therapeutic agents
AU3988099A (en) Combination therapy for treating hypercholesterolemia
GB9902881D0 (en) Therapeutic agents
IL136024A0 (en) Combination therapy for the treatment of migraine
ZA991786B (en) Therapeutic treatment for asthma.
GB0020261D0 (en) Therapeutic treatment
GB9914743D0 (en) Therapeutic agents